Alovudine: Medivir

Current Opinion in Investigational Drugs

Volumn 4, Issue 2, 2003, Pages 219-223

  Rusconi, Stefano ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE; ACETAZOLAMIDE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CL 184824; DIDANOSINE; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; THYMIDINE; ZIDOVUDINE;

ANEMIA; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; BLOOD TOXICITY; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SYNTHESIS; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOPENIA; NEUTROPENIA; NONHUMAN; PROPHYLAXIS; REVIEW; STRUCTURE ACTIVITY RELATION; VIRUS RESISTANCE;

CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DIDEOXYNUCLEOSIDES; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037302387     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. 21145 Metabolism of 3′-azido-3′-deoxythymidine and 3′-fluoro-3′-deoxythymidine in combination in human immunodeficiency virus infected lymphoblastoid cells. Cox S Antiviral Chem Chemother 1992 3 165-170 Paper describing in vitro metabolism of AZT and FLT.
2. 21146 Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-azido-3′-deoxythymidine. Kong X-B, Zhu Q-Y, Vidal PM, Watanabe KA, Polsky B, Armstrong D, Ostrander M, Lang SA Jr, Muchmore E, Chou T-C Antimicrob Agents Chemother 1992 36 4 808-818 Paper describing in vitro effect, transport and pharmacokinetics of FLT and AZT.
3. 21148 Synthesis of 3′-ethynylthymidine, 3′-vinylthymidine and 3′-bromovinylthymidine as potential antiviral agents. Sahlberg C Tetrahedron Lett 1992 33 5 679-682
4. 1H-NMR spectroscopy and molecular mechanics (MM2) calculations. Plavec J, Koole LH, Sandstrom A, Chattopadhyaya J Tetrahedron 1991 47 7363-7376
5. 21150 Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. Munch-Petersen B, Cloos L, Tyrsted G, Eriksson S J Biol Chem 1991 266 14 9032-9038 Paper describing the phosphorylation of AZT, FLT and stavudine in human cells.
6. 81347 Anti-retrovirus activity of 3′-fluoro- and 3′-azido-substituted pyrimidine 2′,3′-dideoxynucleoside analogues. Balzarini J, Baba M, Pauwels R, Herdewijn P, De Clercq E Biochem Pharmacol 1988 37 14 2847-2856 Paper describing in vitro effects of FLT, AZT and related nucleosides.
7. 114655 Prevention of HIV-2 and SIV infections in cynomolgus macaques by prophylactic treatment with 3′-fluorothymidine. Bottiger D, Putkonen P, Oberg B AIDS Res Hum Retroviruses 1992 8 7 1235-1238 Paper describing the prophylactic effect of FLT against HIV-2 and SIV infections in cynomolgus monkeys.
8. 118054 Penetration of zidovudine and 3′-fluoro-3′-deoxythymidine into the brain, muscle tissue, and veins in cynomolgus monkeys: Relation to antiviral action. Ljungdahl-Stahle E, Guzenda E, Bottiger D, Wahren B, Oberg B, Stahle L Antimicrob Agents Chemother 1992 36 11 2418-2422 The concentrations of FLT and AZT in the brain of cynomolgus monkeys, administered subcutaneously with a dose of 25 mg of AZT or FLT were lower than that in muscle and veins. However, the extracellular concentrations of unbound FLT and AZT in the brain and peripheral tissues exceed in vitro antiviral concentrations.
9. 118288 An efficient synthesis of 3′-fluoro-3′-deoxythymidine (FLT). Hager MW, Liotta DC Tetrahedron Lett 1992 33 47 7083-7086
10. 158496 Alovudine. Hoshi A, Castaner J Drugs Future 1994 19 3 221-224
11. 229639 Current antiviral agents factfile. 2nd edition: Part II - Human immunodeficiency viruses. Kinchington D, Minshull C, Drummond C Int Antiviral News 1996 4 7 132-144
12. 396569 Relationship between plasma concentrations of 3′-deoxy-3′fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials. Flexner C, Van Der Horst C, Jacobson MA, Powderly W, Duncanson F, Ganes D, Barditch-Crovo PA, Petty BG, Baron PA, Armstrong D, Brichmont P et al J Infect Dis 1994 170 6 1394-1403
13. 426982 Medivir: Phase IIa clinical trial commenced with MIV-310 targeting multiresistant HIV. Medivir AB Press Release 2001 October 25
14. 430262 Anti-HIV type 1 activity of 3′-fluoro-3′-deoxythymidine for several different multidrug-resistant mutants. Kim EY, Vrang L, Oberg B, Merigan TC AIDS Res Hum Retroviruses 2001 17 5 401-407
15. 430263 Transport of alovudine (3′-fluorothymidine) into the brain and the cerebrospinal fluid of the rat, studied by microdialysis. Stahle L, Borg N Life Sci 2000 66 19 1805-1816
16. 430355 Comparison of the sensitivities of primary isolates of HIV type 2 and HIV type 1 to antiviral drugs and drug combinations. Cox SW, Aperia K, Albert J, Wahren B AIDS Res Hum Retroviruses 1994 10 12 1725-1729
17. 430360 Effect of resistance on combination chemotherapy for human immunodeficiency virus infection. Cox SW, Albert J, Ljungdahl-Stahle E, Wahren B Adv Enzyme Regul 1993 33 27-36
18. 441610 Medivir financial statement, 1 January-31 December 2001. Medivir AB Press Release 2002 February 15
19. 449917 Medivir: Annual report 2001. Medivir AB Annual Report 2002 February 19
20. 457811 Medivir, interim report, 1 January-30 June 2002. Medivir AB Press Release 2002 July 08
21. 475353 Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD N Engl J Med 1998 338 13 853-860
22. 475354 Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. Hogg RS, Heath KV, Yip B, Craib KJ, O'Shaughnessy MV, Schechter MT, Montaner JS J Am Med Assoc 1998 279 6 450-454
23. 475356 AIDS across Europe, 1994-98: The EuroSIDA study. Mocroft A, Katlama C, Johnson AM, Pradier C, Antunes F, Mulcahy F, Chiesi A, Phillips AN, Kirk O, Lundgren JD Lancet 2000 356 9226 291-296
24. 475371 3′-Deoxy-3′-fluorothymidine, a new selective inhibitor of DNA-synthesis. Langen P, Etzold G, Hintsche R, Kowollik K Acta Biol Med Ger 1969 23 6 759-766
25. 475376 3′-Deoxy-3′-fluorothymidinetriphosphate: Inhibitor and terminator of DNA synthesis catalysed by DNA polymerase β, terminal deoxynucleotidyl transferase and DNA polymerase I. Matthes E, Lehmann C, Drescher B, Buttner W, Langen P Biomed Biochim Acta 1985 44 10 K63-K73
26. 475382 An analysis of the inhibition of replication of HIV and MuLV by some 3′-blocked pyrimidine analogs. Bazin H, Chattopadhyaya J, Datema R, Ericson AC, Gilljam G, Johansson NG, Hansen J, Koshida R, Moelling K, Oberg B et al Biochem Pharmacol 1989 38 1 109-119 Paper describing in vitro effect, transport and pharmacokinetics of FLT and AZT.
27. 475600 HIV DART 2002 - Frontiers in Drug Development for Antiretroviral Therapies, Naples, FL, USA. Wainberg MA IDDB Meeting Report 2002 December 15-19
28. 477247 MIV-310 reduces markedly viral load in patients with virological failure despite multiple-drug therapy: Results from a 4-week phase II study. Calvez V, Tubiana R, Ghosn J, Wirden M, Marcelin AG, Westling C, Shoen H, Harmenberg J, Mardh G, Oberg B, Katlama C Antiviral Therapy 2002 7 2 Abs S4 Report from the XI International HIV Drug Resistance Workshop, Seville, Spain. Data available from this phase II trial indicated the usefulness of alovudine in patients experiencing multidrug failure.
29. 477249 In vitro effects of MIV-310 (alovudine, 3′-fluorodeoxythymidine, FLT) against HIV mutants. Vrang L, Zhang H, Palmer S, Kim E-Y, Merigan T, Oberg B Antiviral Therapy 2002 7 2 Abs S18 Report from the XI International HIV Drug Resistance Workshop, Seville, Spain. Alovudine demonstrated in vitro activity against HIV-1 harboring multiple RT mutations when tested on viral isolates derived from patients enrolled in a previous trial.
30. 477409 Drug development pipeline: Alovudine. Company Communication 2003 January 27 Cecilia Westling, Project Director, Medivir AB, confirmed that Medivir had been the originating company and had licensed alovudine to American Cyanamid.
31. 477436 Medivir Q3 (02) e-Update. D Carnegie AB 2002 November 05 Analyst report suggesting that if phase IIa trials of alovudine are successful then a licensing deal involving the drug may occur within the next 12 months.